Home
GTBP
GTBP News

Latest GT Biopharma Inc. (GTBP) News on May 17, 2025

GT Biopharma Appoints New Member to its Board of Directors

GlobeNewswire

2 days ago

GT Biopharma Appoints New Member to its Board of Directors

GT Biopharma Appoints New Member to its Board of Directors

GlobeNewswire

3 days ago

GT Biopharma Appoints New Member to its Board of Directors

GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit

GlobeNewswire

2 months ago

GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit

GT Biopharma Announces Exercise of Warrants

GlobeNewswire

3 months ago

GT Biopharma Announces Exercise of Warrants

GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement

GlobeNewswire

3 months ago

GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies

GlobeNewswire

4 months ago

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies

GT Biopharma Reports Third Quarter 2024 Financial Results

GlobeNewswire

6 months ago

GT Biopharma Reports Third Quarter 2024 Financial Results

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GlobeNewswire

8 months ago

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

GlobeNewswire

8 months ago

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

9 months ago

GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

GlobeNewswire

a year ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

With 58% ownership, Berliner Effektengesellschaft AG (FRA:BFV) insiders have a lot at stake

Simply Wall St.

a year ago

With 58% ownership, Berliner Effektengesellschaft AG (FRA:BFV) insiders have a lot at stake

Better AI Stock: Palantir vs. Snowflake

Motley Fool

a year ago

Better AI Stock: Palantir vs. Snowflake

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?

Motley Fool

a year ago

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?

Why We Like The Returns At CTS Eventim KGaA (ETR:EVD)

Simply Wall St.

a year ago

Why We Like The Returns At CTS Eventim KGaA (ETR:EVD)

BigBear.ai Stock: Buy, Sell, or Hold?

Motley Fool

a year ago

BigBear.ai Stock: Buy, Sell, or Hold?

Indonesia's first Olympic gymnast encourages others to 'dream higher'

AFP

a year ago

Indonesia's first Olympic gymnast encourages others to 'dream higher'

Where Will CrowdStrike Stock Be in 1 Year?

Motley Fool

a year ago

Where Will CrowdStrike Stock Be in 1 Year?

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

GuruFocus.com

a year ago

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire

a year ago

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

GlobeNewswire

a year ago

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

GlobeNewswire

a year ago

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Ostin Technology Group Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

GlobeNewswire

a year ago

Ostin Technology Group Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

MDJM LTD Issues Letter to Shareholders Regarding Strategic Focus and Progress in UK Market Initiatives

PR Newswire

a year ago

MDJM LTD Issues Letter to Shareholders Regarding Strategic Focus and Progress in UK Market Initiatives

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

GlobeNewswire

a year ago

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

SPECTAIRE ANNOUNCES THE COMPLETION OF THE FORWARD PURCHASE AGREEMENT WITH METEORA FUNDS

PR Newswire

a year ago

SPECTAIRE ANNOUNCES THE COMPLETION OF THE FORWARD PURCHASE AGREEMENT WITH METEORA FUNDS

Hyperfine, Inc. Launches AI-powered Brain Imaging Software for Enhanced Image Quality and Ease of Use

Business Wire

a year ago

Hyperfine, Inc. Launches AI-powered Brain Imaging Software for Enhanced Image Quality and Ease of Use

Atara Biotherapeutics Announces $15 Million Registered Direct Offering

Business Wire

a year ago

Atara Biotherapeutics Announces $15 Million Registered Direct Offering

Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

GlobeNewswire

a year ago

Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

Business Wire

a year ago

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

GlobeNewswire

a year ago

Asia Pacific Wire & Cable Corporation Limited Reports Third Quarter 2023 Financial Results

Be Wary Of Asia Pacific Wire & Cable (NASDAQ:APWC) And Its Returns On Capital

Simply Wall St.

a year ago

Be Wary Of Asia Pacific Wire & Cable (NASDAQ:APWC) And Its Returns On Capital

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

GlobeNewswire

a year ago

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

Hain Celestial Group Announces Amber Jefferson as New Chief People Officer

PR Newswire

a year ago

Hain Celestial Group Announces Amber Jefferson as New Chief People Officer

IZEA Acquires Advocate Marketing Platform Zuberance

GlobeNewswire

a year ago

IZEA Acquires Advocate Marketing Platform Zuberance

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

GlobeNewswire

a year ago

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

AG Mortgage Investment Trust, Inc. Completes Acquisition of Western Asset Mortgage Capital Corporation

Business Wire

a year ago

AG Mortgage Investment Trust, Inc. Completes Acquisition of Western Asset Mortgage Capital Corporation

Carbon Revolution Announces First Fiscal Quarter FY2024 Business Update Conference Call Date

GlobeNewswire

a year ago

Carbon Revolution Announces First Fiscal Quarter FY2024 Business Update Conference Call Date

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

GlobeNewswire

a year ago

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

Yoshitsu Co., Ltd Announces the Launch of its U.S. Direct-Sale Store in Seattle’s University District

GlobeNewswire

a year ago

Yoshitsu Co., Ltd Announces the Launch of its U.S. Direct-Sale Store in Seattle’s University District

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

ACCESSWIRE

a year ago

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

PR Newswire

a year ago

MultiMetaVerse Announces Updates of the Taomee Acqusition and Termination of Prior Acquisition Agreement

PR Newswire

a year ago

MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time

PR Newswire

a year ago

MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a

PR Newswire

a year ago

MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2

ARK Survival Ascended Sells 600,000+ Units on Steam During First Two Weeks of Launch

GlobeNewswire

2 years ago

ARK Survival Ascended Sells 600,000+ Units on Steam During First Two Weeks of Launch

iPower Inc. (NASDAQ:IPW) Q1 2024 Earnings Call Transcript

Insider Monkey

2 years ago

iPower Inc. (NASDAQ:IPW) Q1 2024 Earnings Call Transcript

Zacks Small Cap Research

2 years ago

MIRA Continues to Pursue New Pain Relief

Zacks Small Cap Research

2 years ago

CTSO: CytoSorbents reports 3rd quarter 2023 financial and operating results which showed strong product revenue growth and an improved cost structure.

GlobeNewswire

2 years ago

iCAD to Participate in the 14th Annual Craig-Hallum Alpha Select Conference

Sphere 3D Reports Third Quarter 2023 Financial Results and Operational Updates

Newsfile

2 years ago

Sphere 3D Reports Third Quarter 2023 Financial Results and Operational Updates

Thomson Reuters StreetEvents

2 years ago

Q3 2023 Cytosorbents Corp Earnings Call

Fury Intercepts up to 279 g/t Gold over 1.5m at Percival Main

ACCESSWIRE

2 years ago

Fury Intercepts up to 279 g/t Gold over 1.5m at Percival Main

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

GlobeNewswire

2 years ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Share on Social Networks: